Levoflox (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing these processes, the drug stops bacterial cell division and leads to bacterial cell death, providing a bactericidal effect against a broad range of pathogens.

The specific dose and duration of Levoflox therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local guidelines. Healthcare professionals should follow the individualized prescription provided for each patient.

Levoflox is classified as Pregnancy Category C, meaning risk to the fetus cannot be ruled out. It should only be used during pregnancy when the potential benefit justifies the potential risk. Limited data are available for breastfeeding; caution is advised and a risk‑benefit assessment should be performed.

To order Levoflox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Levoflox (levofloxacin) is the L‑isomer of ofloxacin, offering broader Gram‑negative coverage and higher potency against many respiratory pathogens compared with earlier fluoroquinolones. It is often preferred for severe infections due to its once‑daily dosing and favorable pharmacokinetic profile, though resistance patterns and safety considerations remain similar across the class.

Levoflox should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Levoflox is administered intravenously by slow infusion, typically over 30‑60 minutes, under the supervision of qualified healthcare personnel. The exact infusion rate and duration are dictated by the prescribing information and patient-specific factors.

Serious risks include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, and Clostridioides difficile‑associated colitis. Patients should be monitored for sudden tendon pain, cardiac symptoms, or severe diarrhea, and the drug should be discontinued if any of these events occur.

Levoflox is contraindicated in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone therapy, those with uncontrolled QT prolongation, and patients receiving concomitant drugs that markedly increase the risk of tendon injury.